Top 10 Peptide Companies in the USA Transforming Weight Loss Treatment

A few years ago, weight loss medicines were rarely seen as breakthrough healthcare products. Most treatments offered only modest results, and many patients struggled to maintain long-term progress. Then peptide-based therapies changed the entire conversation.

Today, obesity treatment has become one of the fastest-growing areas in the pharmaceutical industry. In the United States, where more than 40% of adults are affected by obesity, pharmaceutical companies are investing billions of dollars to develop advanced peptide drugs that can help people lose significant amounts of weight while improving metabolic health.

The story began gaining momentum when GLP-1 medicines started showing results far beyond expectations. Patients were no longer losing just a few kilograms. Many clinical trials began reporting average body weight reductions of 15% to nearly 20%, numbers that completely reshaped the weight management market.

At the center of this transformation are a group of powerful pharmaceutical and biotechnology companies competing to lead the next generation of obesity treatment.

Eli Lilly: The Company Leading the New Weight Loss Race

Among all companies, Eli Lilly quickly emerged as one of the strongest leaders in the obesity peptide market. Its blockbuster medicines, Mounjaro and Zepbound, transformed the company into a dominant force in metabolic healthcare.

The success was massive. Zepbound generated nearly $13.5 billion in sales during 2025, while Mounjaro reached around $22.9 billion globally. These numbers reflected not only strong patient demand but also the growing confidence doctors had in peptide-based obesity therapies.

But Eli Lilly did not stop there. The company pushed further with retatrutide, a next-generation triple-action peptide drug. In late-stage clinical trials, patients lost more than 28% of their body weight, one of the strongest results ever seen in obesity medicine.

The company’s aggressive innovation strategy placed it at the center of the global obesity treatment revolution.

Novo Nordisk: The Pioneer That Changed the Market

Before the current obesity drug boom fully exploded, Novo Nordisk had already laid the foundation with Wegovy and Ozempic.

Although headquartered in Denmark, the company became a dominant player across the United States. Its semaglutide franchise generated approximately $30.8 billion in sales during 2024, making it one of the most commercially successful pharmaceutical categories in the world.

Wegovy changed public perception about obesity treatment. For the first time, millions of people viewed medical weight management as a scientifically advanced healthcare solution rather than simply dieting or exercise alone.

Novo Nordisk’s early success also forced competitors to accelerate their own peptide drug development programs.

Amgen and the Push Toward Monthly Weight Loss Injections

As competition intensified, Amgen entered the market with a different vision. Instead of weekly injections, the company focused on developing MariTide, a long-acting monthly obesity injection.

Amgen generated approximately $33.4 billion in total company revenue during 2024 and positioned MariTide as a potential convenience-focused alternative for patients who prefer fewer injections.

The idea of monthly peptide therapy quickly attracted attention because convenience is becoming an important factor in long-term obesity treatment adherence.

Pfizer’s Plan to Simplify Obesity Treatment

Pfizer saw another opportunity in the market: oral peptide medicines.

While most major obesity drugs require injections, Pfizer focused heavily on developing oral GLP-1 therapies that could simplify treatment for millions of patients worldwide.

With approximately $63.6 billion in company revenue during 2024, Pfizer has the financial strength to compete aggressively in this rapidly expanding sector.

Its strategy reflects a larger industry trend where companies are trying to make obesity treatment easier, more accessible, and more scalable.

Rising Biotech Players Enter the Market

Alongside pharmaceutical giants, smaller biotechnology companies also began gaining attention.

AbbVie continued expanding its metabolic and gastrointestinal treatment pipeline while reporting roughly $56.3 billion in annual revenue.

Structure Therapeutics focused on oral GLP-1 receptor agonists designed to reduce some of the digestive side effects commonly associated with current obesity drugs.

Viking Therapeutics became one of the most closely watched biotech firms after early studies of VK2735 showed strong weight loss potential. Investors and healthcare analysts quickly began viewing the company as a serious future competitor in the dual GLP-1/GIP therapy market.

Altimmune entered the race with pemvidutide, a peptide therapy designed not only for obesity treatment but also for preserving lean muscle mass during fat reduction.

Metsera, one of the newer companies in the sector, attracted significant market attention as investors searched for emerging obesity drug innovators capable of competing in the next generation of metabolic healthcare.

The Digital Healthcare Companies Expanding Access

The obesity treatment boom also created opportunities beyond drug manufacturing.

Hims & Hers Health became one of the most visible telehealth platforms providing consumer access to weight loss medications, including compounded GLP-1 therapies.

Its digital healthcare model helped expand obesity treatment accessibility for people who preferred online consultations and home-based healthcare services.

Statistical Snapshot of the Weight Loss Peptide Market

A Market That Is Still Growing

The competition among peptide companies continues becoming more intense every year. Researchers are now developing stronger therapies, longer-lasting injections, oral alternatives, and treatments focused on preserving muscle while reducing body fat.

What once looked like a niche category has now become one of the most valuable pharmaceutical markets in the world.

For millions of patients struggling with obesity and metabolic disorders, peptide-based medicines are no longer seen as experimental science. They are rapidly becoming the future of weight management itself.